Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Business & Industry
- FDA approves asthma indication for Dupixent® (dupilumab)
- Amgen invests £50 million ($66 Million) in Oxford Nanopore Technologies
- US FDA grants Lynparza Orphan Drug Designation for pancreatic cancer
- Amgen launches AMGEVITATM (biosimilar adalimumab) in markets across Europe
- Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis
Research & Development
- Eating leafy greens could help prevent macular degeneration
- Targeted drugs for advanced cancer move from specialist units to community setting
- Diets rich in fish oil could slow the spread and growth of breast cancer cells
- Cancer stem cells use normal genes in abnormal ways
- Organs-on-chip technology reveals new drug candidates for Lou Gehrig's disease
- Seed oils are best for LDL cholesterol
- Could treating psoriasis in the future be as easy as going online?
Conferences & Events
- SMi Group announces the 10th Annual RNA Therapeutics Conference
- Pre-Filled Syringes & Injectable Drug Devices Europe 2018
- Social Media in the Pharmaceutical Industry Conference 2019
- Lyophilization USA Conference 2018
- SMi presents the 13th annual industry leading conference: Cold Chain Distribution
- Orphan Drugs and Rare Diseases Conference 2018
- Immuno-Oncology Conference 2018
Regulatory Affairs
- FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old
- FDA approves first treatment for advanced form of the second most common skin cancer
- FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases
- FDA approves new kind of treatment for hairy cell leukemia
- FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease